投稿信息
投稿信息
审稿周期
投稿命中率
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
8.3 %
年文章数
1628
作者需知
暂无数据
NCBI查询
偏重的研究方向
暂无数据
期刊简介
稿件收录要求
稿件收录要求
Drug Safety is the only international review journal covering the disciplines of pharmacovigilance, pharmacoepidemiology and benefit-risk assessment. Drug Safety's structured programme of peer reviewed commissioned articles ensures comprehensive coverage of all topics. High quality original research focusing on the clinical implications of drug treatment safety issues is also published. Drug Safety specialises in definitive reviews on the epidemiology, clinical features, prevention and management of adverse effects of individual drugs or drug classes. Benefit-risk assessments provide you with an in-depth review of adverse effect and efficacy data for a drug in a specific disease. Drug Safety also features reviews covering drug use in particular 'at-risk' patient groups, and concept reviews of current thinking in pharmacovigilance, risk minimisation and medication error prevention. Articles focus on the practical aspects of ensuring the safest possible use of drugs, including analysis and interpretation of adverse effects, post-marketing surveillance and pharmacoepidemiology.
